Drug-Induced Liver Injury: Recent Advances in the Understanding of Pathophysiology and Progress towards Therapeutics
A special issue of Livers (ISSN 2673-4389).
Deadline for manuscript submissions: closed (20 July 2021) | Viewed by 5079
Special Issue Editor
Interests: drug induced liver injury; acute liver failure; innate immune response; mitochondrial dysfunction; oxidative and nitrosative stress
Special Issue Information
Dear Colleagues,
Drug-induced liver injury is one of the most common causes of acute liver failure in the Western world, with acetaminophen overdose being the majority of cases. However, liver injury due to herbal and dietary supplements, as well as newer therapies like immune check point inhibitors, are increasingly prevalent. While mechanistic investigations of liver injury caused by these drugs are ongoing, the current antidote for APAP overdose, N-acetyl cysteine (NAC), also has limitations, especially in late presenting patients. This has led to extensive research on alternate therapeutic strategies to complement NAC, with some progress in recent years towards putative candidates. Thus, research into mechanisms of liver injury caused by APAP overdose and other drugs and supplements are areas of intense interest with significant clinical implication. This Special Issue of Livers will cover all aspects of the pathophysiology of drug-induced liver injury and welcomes both original research as well as expert reviews of topical interest on the subject.
Dr. Anup Ramachandran
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Drug-induced liver injury
- Acetaminophen
- Mitochondria
- Idiosyncratic
- Isoniazid
- Rifampicin
- Herbal medicine
- Dietary supplements
- Check-point inhibitors
- Necrosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
